SimpsonEL, GooderhamM, WollenbergA, et al.; ADhere Investigators. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: A randomized clinical trial (ADhere). JAMA Dermatol. 2023; 159(2):182–191; doi: 10.1001/jamadermatol.2022.5534
2.
WarrenRB, de Bruin-WellerM, TsianakasA, et al.Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: A placebo-controlled, randomized phase IIIb clinical study (ADvantage). Br J Dermatol. 2025; 193(5):876–888; doi: 10.1093/bjd/ljaf285
3.
HaginoT, UchiyamaA, OndaM, et al.Real-world effectiveness and safety of lebrikizumab for moderate-to-severe atopic dermatitis: A 16-week study in Japan. Dermatitis. 2025; 20; doi: 10.1089/derm.2025.0004
4.
AvalloneG, BombelliA, GargiuloL, et al.Effectiveness, safety, and health-related quality of life in moderate-to-severe atopic dermatitis treated with lebrikizumab: A 16-week nationwide retrospective cohort study. Dermatol Ther (Heidelb). 2025; 15(12):3671–3688; doi: 10.1007/s13555-025-01550-8
5.
Armario‐HitaJC, Galán‐GutierrezM, Pereyra‐RodríguezJJ, et al.Real‐world effectiveness and safety of lebrikizumab in moderate‐to‐severe atopic dermatitis: A multicenter study from Spain. Int J Dermatology. 2025:70185; doi: 10.1111/ijd.70185
